Evidence map›Paper›PMID 31635385›Full record

ArticleJournal of clinical medicine2019

Positive Impact of Expert Reference Center Validation on Performance of Next-Generation Sequencing for Genetic Diagnosis of Autoinflammatory Diseases.

Guilaine Boursier, Cécile Rittore, Sophie Georgin-Lavialle, Alexandre Belot, Caroline Galeotti, Eric Hachulla, Véronique Hentgen, Linda Rossi-Semerano, Guillaume Sarrabay, Isabelle Touitou

Abstract read
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Article
  3. Variant in theJournal of clinical medicine · 2022
    Article
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Guilaine BoursierDepartment of Medical Genetics, Rare Diseases and Personalized Medicine, CHU Montpellier, Rare and Autoinflammatory diseases unit, Univ Montpellier, 34295 Montpellier, France. g-boursier@chu-montpellier.fr.
Cécile RittoreDepartment of Medical Genetics, Rare Diseases and Personalized Medicine, CHU Montpellier, Rare and Autoinflammatory diseases unit, Univ Montpellier, 34295 Montpellier, France. cecile.rittore@inserm.fr.
Sophie Georgin-LavialleDepartment of Internal Medicine, CEREMAIA, Tenon Hospital, AP-HP, University of Pierre et Marie Curie, 75970 Paris, France. sophie.georgin-lavialle@aphp.fr.
Alexandre BelotPaediatric Nephrology, Rheumatology, Dermatology Unit, RAISE, HFME, HCL, Univ Lyon, 69677 Bron, France. alexandre.belot@chu-lyon.fr.
Caroline GaleottiDepartment of Paediatric Rheumatology, CEREMAIA, Bicêtre Hospital, AP-HP, 94275 Le Kremlin-Bicêtre, France. caroline.galeotti@aphp.fr.
Eric HachullaDepartment of Internal Medicine and Clinical Immunology, CHU Lille, University of Lille, 59037 Lille, France. Eric.HACHULLA@chru-lille.fr.
Véronique HentgenDepartment of General Pediatrics, CEREMAIA, CH Versailles, 78157 Le Chesnay, France. vhentgen@ch-versailles.fr.
Linda Rossi-SemeranoDepartment of Paediatric Rheumatology, CEREMAIA, Bicêtre Hospital, AP-HP, 94275 Le Kremlin-Bicêtre, France. linda.rossi@aphp.fr.
Guillaume SarrabayCellules souches, plasticité cellulaire, médecine régénératrice et immunothérapies, INSERM, University Montpellier, Department of Medical Genetics, Rare Diseases and Personalized Medicine, CEREMAIA, CHU Montpellier, 34295 Montpellier, France. guillaume.sarrabay@inserm.fr.
Isabelle TouitouCellules souches, plasticité cellulaire, médecine régénératrice et immunothérapies, INSERM, University Montpellier, Department of Medical Genetics, Rare Diseases and Personalized Medicine, CEREMAIA, CHU Montpellier, 34295 Montpellier, France. isabelle.touitou@inserm.fr.

Funding

Ministère des Affaires Sociales et de la Santé No grant. Funding as National Reference Center.
6 · The paper itself

Abstract

Monogenic autoinflammatory diseases (AIDs) are caused by variants in genes that regulate innate immunity. The current diagnostic performance of targeted next-generation sequencing (NGS) for AIDs is low. We assessed whether pre-analytic advice from expert clinicians could help improve NGS performance from our 4 years of experience with the sequencing of a panel of 55 AIDs genes. The study included all patients who underwent routine NGS testing between September 2014 and January 2019 at the laboratory of autoinflammatory diseases (Montpellier, France). Before March 2018, all medical requests for testing were accepted. After this time, we required validation by a reference center before NGS: the positive advice could be obtained after a face-to-face consultation with the patient or presentation of the patient's case at a multidisciplinary staff meeting. Targeted NGS resulted in an overall 7% genetic confirmation, which is consistent with recent reports. The diagnostic performance before and after implementation of the new pre-requisite increased from 6% to 10% (

Indexed as

autoinflammatory diseasesmultidisciplinary consultationnext-generation sequencing

Identifiers

PMID31635385
PMCPMC6832712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.